Asset Manager

Updated:

AML Biotech Partners

AML Biotech Partners is an investment firm focused on early-stage biotechnology and life sciences companies. The firm operates from its primary location in...

AML Biotech Partners

AML Biotech Partners is an investment firm focused on early-stage biotechnology and life sciences companies. The firm operates from its primary location in Pasadena, California, with a presence in Summit, New Jersey, Chicago, Illinois, and San Francisco, California. This multi-hub structure positions AML near several of the country's most productive academic and medical research ecosystems. AML Biotech Partners targets therapeutics and platform-technology companies at the earliest stages of development, often engaging with scientific founders around university spinouts. The firm participates in seed and Series A financings across modalities including small molecules, biologics, and enabling life-science tools. Its strategy relies on proximity to dense innovation clusters — the Caltech and greater Los Angeles biomedical community from Pasadena, the pharmaceutical corridor in New Jersey, the Midwest research hospitals from Chicago, and the Bay Area venture-science nexus from San Francisco. Operational details on team size and total committed capital are not publicly disclosed. The absence of a public website with detailed team or portfolio information limits what outside allocators can independently verify about the firm's current deployment pace or fund structure. AML does not maintain a public-facing LinkedIn company page or widely circulated investor letters available to the institutional market. Structurally, AML Biotech Partners represents a strategy built on regional scientific access rather than centralized asset-gathering.

General information

Firm type

Asset Manager

Location

Region

North America

Country

United States

City

Pasadena

Corporate office

Pasadena, CA, United States

Additional offices

Summit, NJ · Chicago, IL · San Francisco, CA

Sector focus

BiotechHealthcare Services

Frequently asked questions

Who runs investment decisions at AML Biotech Partners?

AML Biotech Partners does not publicly disclose its leadership team or investment committee structure. Without a public website detailing its principals, the identities of the firm's managing partners and decision-makers are not verifiable through standard external sources.

What is AML Biotech Partners' known posture on co-investments?

The firm does not publicly state its co-investment policies. Given its participation in early-stage biotech syndicates, third-party allocators interested in co-investment opportunities should engage directly with the firm, as no written co-investment framework is available in the public domain.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on asset managers?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More Pasadena Asset Manager profiles